Gibbel (688566.SH) disclosed the 2023 annual results report. During the reporting period, the company achieved total operating revenue...
According to Zhitong Finance App News, Gibbel (688566.SH) disclosed the 2023 annual results report. During the reporting period, the company achieved total operating revenue of 861 million yuan, an increase of 31.49% over the previous year; net profit attributable to the owner of the parent company was 216 million yuan, an increase of 39.57% over the previous year.
During the reporting period, the company continued to strengthen market development for major products such as licorjun tablets and nitronolol tablets, which had a positive impact and achieved rapid growth in business performance. At the same time, the company actively promoted the research and development process of new drugs such as the new antidepressant JJH201501 and the new anti-tumor drug JJH201601, and made new progress.
